Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1623 1629
This examiner grants 48% of resolved cases
William Y Lee, in Tech Center 1600 and Art Unit 1623, has 710 resolved cases. The allowance rate is 47.9 percent. The interview lift is 34.1 percent, which is a significant boost to the probability of success.
The median days to allowance is 1170. This timeline is based on the 710 resolved cases. The 47.9 percent allowance rate is below a majority, but the 34.1 percent interview lift suggests that interviews are very effective.
In Art Unit 1623, the 1170 median days to allowance is a key planning figure. The allowance rate across resolved cases shows a challenging environment. The interview lift is a helpful metric for practitioners to consider when developing their strategy. This data set provides a clear roadmap for improving prosecution outcomes.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 17727519 | Method of Treating Colorectal Cancers Using a PKC Inhibitor | Final Rejection | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. |
| 18383256 | AGENTS AND METHODS FOR PREVENTING AND TREATING SKELETAL MUSCLE DISEASES | Non-Final OA | The Regents Of the University of California |
| 18567952 | PESTICIDALLY ACTIVE DIAZINE-AMIDE COMPOUNDS | Non-Final OA | SYNGENTA CROP PROTECTION AG |
| 18480409 | CDK4/6 INHIBITORS AS A TREATMENT FOR CLONAL HEMATOPOIESIS | Non-Final OA | Washington University |
| 18201882 | MULTIBIOTIC AGENTS AND METHODS OF USING THE SAME | Non-Final OA | Flagship Pioneering Innovations V, Inc. |
| 18237705 | COMPOSITIONS AND METHODS FOR IMPROVED TREATMENT OF PLATINUM-BASED CHEMOTHERAPEUTIC RESISTANT TUMORS | Non-Final OA | THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE |
| 18002433 | DIMETHYL SULFONE FOR TREATMENT OF CHRONICALLY HEAT STRESSED POULTRY | Final Rejection | Evonik Operations GmbH |
| 18291083 | SUBSTITUTED PYRIDONE COMPOUNDS USEFUL TO TREAT ORTHOMYXOVIRUS INFECTIONS | Non-Final OA | NOVARTIS AG |
| 18113981 | COMPOSITIONS AND METHODS FOR TREATING NEURODEGENERATIVE DISORDERS | Non-Final OA | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK |
| 18690228 | INK4 TUMOR SUPPRESSOR PROTEINS MEDIATE RESISTANCE TO CDK4/6 KINASE INHIBITORS | Non-Final OA | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH |
| 15516444 | ATROPINE SULFATE RAPIDLY-DISINTEGRATING SUBLINGUAL TABLETS AND METHODS FOR USE THEREOF FOR TREATMENT OF ACUTE ORGANOPHOSPHATE TOXICITY | Final Rejection | University of Sharjah |
| 18400602 | NOVEL MKRN1 INHIBITOR AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING OBESITY OR FATTY LIVER COMPRISING THE SAME | Non-Final OA | UIF (University Industry Foundation), Yosei University |
| 18280357 | Pelargonic Acid for Use Against Viral Infections | Non-Final OA | Nutrition Sciences N.V. |
| 17601148 | USE OF GINKGO TERPENE LACTONE IN PREPARING DRUG FOR PREVENTING AND/OR TREATING GUILLAIN-BARRE-STROHL SYNDROME | Final Rejection | CHENGDU BAIYU PHARMACEUTICAL CO., LTD. |
| 17252481 | PLASMALOGEN-CONTAINING COMPOSITION | Final Rejection | MARUDAI FOOD CO., LTD. |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy